![Sarina Chohan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sarina Chohan
No más puestos en curso
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Steven Watkins | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 9 años |
Ryan Davis | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 9 años |
Michael J. Miille | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
Roger Salquist | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
Scott Lenet | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
Anula Kusum Jayasuriya | M | 67 |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | - |
Jeffrey McDonald | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 8 años |
Michelle Wiest | M | - |
Lipomics Technologies, Inc.
![]() Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 8 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Sarina Chohan
- Red Personal